Resource impact statement

Cancer Drugs Fund technology

NICE has recommended venetoclax for use within the Cancer Drugs Fund for treating chronic lymphocytic leukaemia.

Venetoclax will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and AbbVie have a commercial access agreement that makes venetoclax available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of venetoclax will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed when the results of the managed access agreement data collection are available, which is expected to end in December 2020. As part of the managed access agreement, the technology will continue to be available through the Cancer Drugs Fund after the data collection period has ended and while the guidance is being reviewed. This assumes that the data collection period ends as planned and the review of guidance follows the standard timelines described in the addendum to NICE’s methods and processes when appraising cancer technologies.

Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.

It is estimated that 240 people per year with chronic lymphocytic leukaemia are eligible for treatment with venetoclax.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 08 November 2017